3-hydroxybutyric acid has been researched along with B16 Melanoma in 2 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrere, G | 1 |
| Tidjani Alou, M | 1 |
| Liu, P | 1 |
| Goubet, AG | 1 |
| Fidelle, M | 1 |
| Kepp, O | 1 |
| Durand, S | 1 |
| Iebba, V | 1 |
| Fluckiger, A | 1 |
| Daillère, R | 1 |
| Thelemaque, C | 1 |
| Grajeda-Iglesias, C | 1 |
| Alves Costa Silva, C | 1 |
| Aprahamian, F | 1 |
| Lefevre, D | 1 |
| Zhao, L | 1 |
| Ryffel, B | 1 |
| Colomba, E | 1 |
| Arnedos, M | 1 |
| Drubay, D | 1 |
| Rauber, C | 1 |
| Raoult, D | 1 |
| Asnicar, F | 1 |
| Spector, T | 1 |
| Segata, N | 1 |
| Derosa, L | 1 |
| Kroemer, G | 1 |
| Zitvogel, L | 1 |
| Piddubnyak, V | 1 |
| Kurcok, P | 1 |
| Matuszowicz, A | 1 |
| Głowala, M | 1 |
| Fiszer-Kierzkowska, A | 1 |
| Jedliński, Z | 1 |
| Juzwa, M | 1 |
| Krawczyk, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma[NCT05119010] | 60 participants (Anticipated) | Interventional | 2023-03-24 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for 3-hydroxybutyric acid and B16 Melanoma
| Article | Year |
|---|---|
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade.
Topics: 3-Hydroxybutyric Acid; Animals; Cell Line, Tumor; Combined Modality Therapy; CTLA-4 Antigen; Diet, K | 2021 |
Oligo-3-hydroxybutyrates as potential carriers for drug delivery.
Topics: 3-Hydroxybutyric Acid; Animals; Biocompatible Materials; Blotting, Western; Cell Line; Cell Line, Tr | 2004 |